LeafNLP Demos
Back to explore

Report #2876756

Received Dec 8, 2025

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
68 yrs
State
FL
Recovered
Unknown
Vaccinated
Jun 10, 2025
Onset
Jun 10, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS2——

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

patient that received a late second dose of Shingrix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 20-OCT-2023 with batch number 7YD42 and lot expiry 02-MAY-2027). On 10-JUN-2025, the patient received the 2nd dose of Shingrix. On 10-JUN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient that received a late second dose of Shingrix). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 04-DEC-2025 The pharmacist wanted to know how to proceed with the herpes zoster immunization series in a patient that received a late second dose of Shingrix. The vaccine administration facility was the same as primary reporter. The batch number was not provided upon follow up with the reporter.